Rainer Metcalf

Rainer Metcalf's work experience began in 2003 as a Radiology Technician at Morton Plant Mease. From 2006 to 2007, they worked as a Chemical Technician and Metals Analyst at Southern Analytical Laboratories. In 2012, they became a Core Research Specialist at Moffitt Cancer Center, specializing in computational biology techniques. In 2015, they co-founded CUPRX, LLC, focusing on the development of copper activated anti-cancer drugs. At the University of South Florida, they worked as a Graduate Research Assistant from 2010 to 2019 and as a Graduate Teaching Assistant from 2011 to 2019. Rainer also worked as a Computational Chemist at Ibis Therapeutics from 2019 to 2020 and as a Scientific Consultant at the University of South Florida from 2020 to 2020. In 2020, they joined Venn Therapeutics as the Director of Computational Chemistry, and in 2021, they became a member of the Scientific Advisory Board at Ibis Therapeutics. Currently, they are serving as the Chief Technology Officer at Asha Therapeutics, where they are leading the development of drug discovery technologies.

Rainer Metcalf's education history begins in 2006 when they enrolled at the University of South Florida. Over the course of four years, from 2006 to 2010, they pursued a Bachelor of Science (B.S.) degree in Physics. Following their undergraduate studies, they continued their academic journey at the same university, this time focusing on Chemistry. Starting in 2011, Rainer embarked on a doctoral program and eventually obtained their Doctor of Philosophy (PhD) degree in Chemistry in 2019, after eight years of research and study.